Lewy Body Dementia Treatment Market Report 2026

The lewy body dementia treatment market size has grown strongly in recent years. It will grow from $4.69 billion in 2025 to $5.02 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing prevalence of dementia disorders, limited curative treatment options, long-term clinical use of symptomatic drugs, rising geriatric population, growing hospitalization rates for neurological disorders.

The lewy body dementia treatment market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to rising demand for personalized treatment plans, expanding access to neurological care, increasing focus on quality of life improvement, growing availability of advanced drug formulations, higher investment in dementia treatment research. Major trends in the forecast period include increasing use of combination drug therapies, growing reliance on symptom-based treatment approaches, rising adoption of non-pharmacological therapies, expanding use of cholinesterase inhibitors, growing focus on sleep and behavioral symptom management.

The increasing prevalence of brain-related disorders is anticipated to drive the growth of the Lewy body dementia treatment market in the coming years. Brain disorders refer to any condition that impairs the functioning of the brain. The severity of the impairment can range from mild to severe, depending on the extent of brain damage. Lewy body dementia treatment is used to manage brain disorders such as hallucinations, confusion, and drowsiness by enhancing brain chemicals to improve cognition and alertness. For example, in July 2024, the National Health Service, a UK-based government agency, reported that 487,432 patients had been diagnosed with dementia - a progressive brain disorder affecting memory, thinking, and daily activities - by June 30, 2024. Consequently, the rising prevalence of brain-related disorders is fueling the growth of the Lewy body dementia treatment market.

Key companies in the Lewy body dementia treatment market are concentrating on developing innovative therapies, such as monoclonal antibody treatments, which target underlying neurodegenerative processes to enhance cognitive outcomes and slow disease progression compared with conventional symptomatic treatments that have limited effects on disease pathology. Monoclonal antibodies help reduce toxic protein accumulation in the brain, addressing key contributors to cognitive decline in dementia-related disorders. For instance, in January 2023, Biogen Inc., a US-based multinational biotechnology company, developed lecanemab, a humanized monoclonal antibody used to treat Alzheimer's disease, which is associated with Lewy body dementia. A major benefit of lecanemab is its ability to reduce brain amyloid levels, treating the brain and clearing amyloid plaques believed to cause cognitive impairment and dementia in Alzheimer's disease.

In October 2024, Cognition Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, formed a partnership with the University of Miami Miller School of Medicine to enhance awareness and research efforts for Lewy body dementia (LBD), the second most common type of degenerative dementia. Through this collaboration, Cognition Therapeutics Inc. and the University of Miami Miller School of Medicine aim to deepen understanding of LBD, promote early diagnosis, and accelerate therapeutic development, including programs related to CT1812, Cognition Therapeutics’ investigational synaptic-protective therapy. The University of Miami Miller School of Medicine is a US-based academic medical institution focused on clinical research, medical education, and advanced patient care.

Major companies operating in the lewy body dementia treatment market are Mallinckrodt Pharmaceuticals Co., BioArctic AB, Sumitomo Pharma Co. Ltd., Jazz Pharmaceuticals Inc., Allergan plc, Novartis International AG, Pfizer Inc., Bayer AG, Boehringer Ingelheim International GmbH., Merck & Co. Inc., Biogen Inc., Biohaven Pharmaceutical Holding Company Ltd., Bristol Myers Squibb Company, Calliditas Therapeutics AB, Chiesi USA Inc., GlaxoSmithKline plc, Eisai Co. Ltd., Bausch Health Companies Inc., Hisamitsu Pharmaceutical Co. Inc., Lundbeck Inc.

North America was the largest region in the Lewy body dementia treatment market in 2025. The regions covered in the lewy body dementia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lewy body dementia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the lewy body dementia treatment market by increasing costs associated with imported pharmaceutical ingredients and finished neurological drugs. These impacts are more visible across antidepressants, antipsychotic drugs, and carbidopa-levodopa segments, particularly in regions such as Asia-Pacific and Europe that depend on cross-border drug manufacturing and supply. Hospital and retail pharmacy distribution channels face pricing and availability pressures due to tariff-related cost increases. At the same time, tariffs have encouraged domestic drug production, localized sourcing, and supply chain diversification, supporting long-term market resilience.

The lewy body dementia treatment market research report is one of a series of new reports that provides lewy body dementia treatment market statistics, including lewy body dementia treatment industry global market size, regional shares, competitors with a lewy body dementia treatment market share, detailed lewy body dementia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia treatment industry. This lewy body dementia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lewy body dementia treatment involves the use of medications and nonmedical therapies, such as physical, occupational, and speech therapies, to manage symptoms as effectively as possible. This treatment aims to alleviate and control certain symptoms and to reduce hallucinations, confusion, drowsiness, movement difficulties, and disturbed sleep.

The main drug categories in the lewy body dementia treatment market include antidepressants, antipsychotic drugs, benzodiazepines, carbidopa-levodopa, cholinesterase inhibitors, and modafinil. Antidepressants are medications prescribed to treat depression and are also used for anxiety disorders, obsessive-compulsive disorder (OCD), chronic pain, eating disorders, and post-traumatic stress disorder (PTSD). They function by increasing the levels of specific chemicals in the brain that help enhance mood. The distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, and they are used for conditions such as Alzheimer's disease, dementia, and Parkinson's disease.

The lewy body dementia treatment market consists of revenues earned by entities by providing speech and language therapy, physiotherapy, and psychological therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia treatment market also includes sales of rivastigmine, donepezil, and galantamine products, which are used in providing lewy body dementia treatment services. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.